#USA #Delray Beach #MarketsandMarkets #Contract Manufacturing #Oligonucleotide CDMO

The Oligonucleotide CDMO Market Surge: A Comprehensive Outlook to 2031

The oligonucleotide Contract Development and Manufacturing Organization (CDMO) market is on track to reach a remarkable $11.14 billion by the year 2031. This growth trajectory from $3.88 billion in 2026 reflects an impressive compound annual growth rate (CAGR) of 23.5%, positioning this sector as a pivotal player in the biotechnology field.

Market Dynamics and Trends

The increasing pivot of oligonucleotide programs from preclinical stages to clinical trials and commercial viability is fueling the demand for specialized CDMOs that can cater to diverse phases of the development lifecycle. Pharmaceutical and biotechnology companies are progressively outsourcing critical components such as process and analytical development, synthesis, purification, scale-up, and Good Manufacturing Practices (GMP) manufacturing to specialized CDMOs.

The Need for Integrated Manufacturing Solutions

As sponsors look to minimize technology transfer needs and streamline product quality, the necessity for continuous processes across different development stages is more pronounced than ever. CDMOs boasting scalable solutions to facilitate the transition from small-scale development to large clinical and commercial outputs are in high demand. Moreover, the growing intricacy of modified oligonucleotides is advancing the requirement for specialized synthesis, purification, analytical characterization, and scale-up capabilities. These factors collectively encourage sponsors to partner with CDMOs offering integrated development and production services instead of engaging multiple specialized providers.

Growth by Service Type

When examining the services rendered, contract manufacturing continues to dominate, accounting for 42.1% of the total oligonucleotide CDMO market in 2025. However, the fast-growing segment is anticipated to be contract development services. The increasing trend towards outsourcing oligonucleotide production as projects evolve toward clinical application further drives this rapid growth. Contract development services are expected to garner attention due to rising demand for GMP synthesis, purification, scale-up, and quality control, primarily from robust clinical-stage programs.

Significant Market Segments

In terms of applications, therapeutic uses hold the largest market share, expected to grow further due to the rise in oligonucleotide-focused therapeutics and their demand for GMP manufacturing processes. The healthcare sector continues to expand its preference for outsourcing synthesis, purification, analytical testing, and large-scale production to specialized CDMOs, highlighting a trend closely tied with evolving advancements in Antisense Oligonucleotides (ASO) and small interfering RNA (siRNA) studies.

Importance of North America

Geographic analysis reveals that North America retained 43.2% of the oligonucleotide CDMO market share in 2025, a reflection of the area’s concentration of pharmaceutical and biotech entities with strong oligonucleotide pipelines and well-established manufacturing facilities. This trend is supported by rising needs for scalable production and specialized services, emphasizing the region’s authoritative role in the global market landscape. The maturity of its regulatory environment enhances confidence in developing and manufacturing oligonucleotide therapeutics, encouraging further investments into infrastructure.

Key Players Shaping the Market

Leading entities include Agilent Technologies, Bachem, WuXi AppTec, Thermo Fisher Scientific, and ST Pharm. Together, these companies constitute roughly 50-55% of the global market, signifying a moderately consolidated competitive atmosphere. Their dominant presence comes from extensive service offerings across synthesis, manufacturing, purification, and regulatory support processes.

Strategic Investments and Acquisitions

Investment in the oligonucleotide CDMO market has surged, bolstered by a notable emphasis on expanding solid-phase synthesis capabilities and high-throughput purification lines. This landscape sees growing strategic transactions as companies like Agilent have committed significant financial resources, exceeding $740 million since 2023, to elevate commercial oligonucleotide manufacturing.

Mergers and acquisitions are prevalent as organizations seek to solidify their positions through the expansion of CDMO capabilities. For instance, Maravai LifeSciences' acquisition of Molecular Assemblies enhances its technological advantages within oligonucleotide manufacturing, showcasing the sector's dynamic nature.

Conclusion

Across the board, the oligonucleotide CDMO market is positioned for substantial growth owing to the accelerating demand for therapeutic solutions and advanced manufacturing capabilities. With strategic investments, technological advancements, and a clear trend toward consolidation among key players, the market is set to thrive, ultimately shaping the future of biotechnology and therapeutics in the years to come.